You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

111 search results for: quality of life

Impact <b>of</b> Delayed EoE Diagnosis on Disease Progression and QoL

expert video

Impact of Delayed EoE Diagnosis on Disease Progression and QoL

2 min

Gastroenterology

Join Prof. Arjan Bredenoord as he discusses the importance of early diagnosis of EoE.

Managing the Risk <b>of</b> Fibrostenosis in EoE

expert video

Managing the Risk of Fibrostenosis in EoE

2 min

Gastroenterology

Hear from Drs. Jason Lee, Kathryn Peterson, Seema Aceves, and Ikuo Hirano on disease progression and the importance of managing fibrostenotic risk in EoE.

Explore the Global Burden <b>of</b> Pediatric AD (PEDISTAD)

interactivity

Explore the Global Burden of Pediatric AD (PEDISTAD)

15 min

Dermatology

This interactive tool allows you to explore the global burden of AD in pediatric patients <12 years from the PEDISTAD Study.

Podcast

ADVENT On Air | More Than Just Difficulty Swallowing: EoE Burden and Diagnosis

12 min

Gastroenterology

Hear Dr. Wechsler and Prof. Bredenoord discuss the multifaceted burden of EoE and how to overcome challenges in identifying EoE in clinical practice.

expert video

Children and EoE: More Than Just Being a Picky Eater

9 min

Gastroenterology

Join Prof. Alexandra Papadopoulou as she reviews the multifaceted burden of children with EoE.

expert video

How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

2 min

Rhinology

In this video clip from the EAACI 2024 symposium, Dr. Mullol discusses the challenge of defining active nasal disease using an endoscope.

expert video

Comorbidities and Disease Burden in CSU

10 min

Dermatology

In their interview Drs. Maurer and Ensina shed light on the significant burden of comorbidities in CSU.

expert video

Can Emerging Treatments Help Address Individual PN Patient Burden?

17 min

Dermatology

Prof. Sonja Ständer emphasizes the high patient burden of PN, and how this is influenced by patient needs and comorbidities. She discusses how emerging treatments are reducing patient burden.

expert video

Current Treatment Landscape and Emerging Therapies

16 min

Dermatology

Dr. Lawrence F. Eichenfield reviews the evolving therapeutic landscape for children with AD, considering clinically relevant data supporting the use of advanced systemic therapies. This video was recorded at the EADV 2023 annual meeting during the ‘New Horizons in Children With Atopic Dermatitis: Emerging Evidence in Disease Management’ presentation.

Impact <b>of</b> Type 2 Inflammation on Pediatric Atopic Dermatitis, Asthma and Eosinophilic Esophagitis

expert video

Impact of Type 2 Inflammation on Pediatric Atopic Dermatitis, Asthma and Eosinophilic Esophagitis

9 min

Type 2 Inflammation

Prof. Stephan Weidinger discusses the impact of type 2 inflammation on disease burden and clinical outcomes in pediatric patients.

The Evolving Understanding <b>of</b> Prurigo Nodularis (PN) Has Implications for Patient Management

Infographic

The Evolving Understanding of Prurigo Nodularis (PN) Has Implications for Patient Management

5 min

Dermatology

An infographic summarizing the clinical manifestations and pathophysiological processes of PN.

Importance <b>of</b> Monitoring and Maintenance in EoE

Infographic

Importance of Monitoring and Maintenance in EoE

5 min

Gastroenterology

Learn about patient concerns in EoE and the benefits of adequate monitoring and effective maintenance therapy on disease control and QoL

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: The NetherlandsChange country/region